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Collaboration Between Sdentists,
Clinidans Moves Apoptosis Studies Forward
by Maureen Goode, Ph.D.

o penetrate the
ingenious defenses of cancer
cells that often
make them resistant to therapy, researchers at
The University of Texas M. D.
Anderson Cancer Center are
investigating the use of synthetic peptides that function
as zny assassins- u:rgetinrr-~- -+-------,....;.
tumor cells from the inside
Research by Associate Professor of Cancer Biology David J. Mcconkey, Ph.D., and others
with lethal accuracy.
into the mechanisms of apoptosis recently led to the first clinical trial of the synthesized

These agents, called proteasome
inhibitors, have been shown to
induce high levels of apoptosis, or
programmed cell death, in prostate
cancer cells. Now, studies of proteasome inhibitors at M. D. Anderson
are moving from the lab to a phase I
clinical trial of the synthesized
proteasome inhibitor PS-341.
Apoptosis is a normal, genetically
controlled cellular process that kills
cells in response to certain stimuli.
Affected cells are marked by characteristic morphological changes:

proteasome inhibitor PS-341 in patients with prostate cancer.

They shrink, their chromosomes
condense, their DNA fragments, and
blebs appear on their cell membranes.
The study of apoptosis began in the
1970s, when scientists first detected
these changes in electron m icrographs of rat liver cells.
David]. McConkey, Ph.D., associate professor in the Department of
Cancer Biology at M . D . Anderson, is
studying how apoptosis is disrupted
during tumor progression, especially

in metastatic cells, and how disruptions make cells resistant to therapy.
"Chemotherapeutic agents and
other therapeutic strategies induce
apoptosis in their tumor targets,"
he explained. 'Tumors that become
resistant to treatment appear to
have developed mechanisms to
resist apoptosis. By identifying
those mechanisms, we will identify
the interrupter."
(Continued on next page)

Apoptosis Studies Move Forward
( Continued from page 1)

Unlike necrosis, which kills
normal cells that have experienced
trauma, apoptosis seems to kill only
diseased or unwanted cells. Necrotic
cells burst and cause inflammation
that can damage nearby normal
tissue. In contrast, apoptotic cells
lose contact with neighboring cells
and are removed by the body's
scavenging cells before they burst
and release possibly harmful contents
into the body. This may be the most
important characteristic of apoptosis.
''We think apoptosis may have
evolved as a way to safely remove
large quantities of single cells without
inducing an inflammatory response,"
said Dr. McConkey, who is one of
more than 100 researchers at M. D.
Anderson studying apoptosis. ''Work
over the past decade or so has
revealed that apoptosis is regulated
by an evolutionarily conserved
molecular pathway. The original
studies were conducted in a nematode worm, Caenorhabditis elegans."
The worm studies revealed
that three genes are essential for
apoptosis: ced3, ced4, and ced9,
the worm version of the human
oncogene bcl2, which blocks the
action of the other two genes to
inhibit apoptosis. bcl2 acts through
the caspases, a group of at least 13
of the proteins called proteases. It is
the proteases, which control enzymes
to produce the characteristic DNA
fragmentation seen during apoptosis,
that are the focus of Dr. McConkey' s
studies. Similar research by Timothy
J. McDonnell, M.D., Ph.D., an
associate professor in the Department of Molecular Pathology, is
aimed at determining how bcl2 and
its relatives regulate the responses
of prostate cancer cells to therapy.
''We were looking for other proteases involved in apoptosis and
happened across one called the proteasome that controls an important
survival pathway," Dr. McConkey said.
The proteasome is a huge complex of
14 proteases that degrade the proteins
that control the transit of the cell
through its normal replication cycle.
Preliminary evidence suggested
that the proteasome was involved
2 / MD Anderson OncoLog

in controlling apoptosis in chronic
lymphocytic leukemia cells. Dr.
McConkey and colleagues also found
high proteasome levels in metastatic
and nonmetastatic prostate cancer
cells. Treatment with proteasome
inhibitors induced high levels of
apoptosis in both cell types, even
in cells that were engineered to
overexpress bcl2 and should have
been resistant to apoptosis.
Proteasome inhibitors are 100
to 1000 times more selective for the
proteasome than for the next most
common protein they attack. Dr.
McConkey and others have shown
that proteasome inhibitors can actually
inhibit apoptosis in some normal cells,
thus improving their survival.

"We have found that
treatment of DiFi
human colon cancer cells
with C225 alone induces
apoptosis ... "
- Zhen Fan, M.D., assistant professor,
Department of Experimental Therapeutics
The clinical application of these
findings is typical of M. D. Anderson
collaborations that bring together
scientists and clinicians.
"Fortuitously," said Dr. McConkey,
"I was at a Grand Rounds where
Professor of Pharmacology Robert
A. Newman, M.D., described the proteasome inhibitors as a novel class of
therapeutic agents that were among
the most potent compounds seen in
the National Cancer Institute's drug
screening tests. This, combined with
the activity we had seen against bcl2
in tumors, suggested that proteasome
inhibitors might have therapeutic
potency. So, we met with ProScript,
the company synthesizing the
proteasome inhibitor PS-341."
This led Chairman Christopher
J. Logothetis, M.D., and Assistant
Professor Christos N. Papandreou,
M.D., of the Department of Genitourinary Medical Oncology to
organize the first clinical trial of
PS-341 in patients with advanced

prostate cancer. In this phase I trial,
PS-341 is being administered on an
outpatient basis by intravenous bolus
once a week for fo ur weeks. So far,
21 patients have received the drug.
"In a phase I trial, it's rare to
see efficacy," said Dr. Papandreou.
However, PS-341 has not only been
well tolerated but has also appeared
to reduce tumor size .
A research team led by M. D.
Anderson President John Mendelsohn,
M.D., is also examining apoptosis as a
novel approach for cancer therapy.
Dr. Mendelsohn and colleagues have
pioneered the clinical use of the an tiepidermal growth factor receptor
monoclonal antibody C225, which
inhibits the p roliferation of cancer
cells. In the course of their studies,
they have also linked C225 to apoptosis.
"We found that C225 induces
apoptosis under certain conditions,"
said Zhen Fan, M.D., assistant professor in the Department of Experimental Therapeutics and a close collaborator with Dr. Mendelsohn on the
C225 study. "C225 inhibits the proliferation of many cultured human
cancer cells, and, when administered
concurrently with chemotherapeutic
agents, C225 can kill human tumor
xenografts growing on mice."
These results have provided the
impetus for ongoing phase II and III
clinical trials of C225 combined with
chemotherapy or radiation therapy
in patients with cancers of the pancreas, colon, and head and neck.
'We have found that treatment of
DiFi human colon cancer cells with
C225 alone induces apoptosis, which
is normally not seen unless C225 is
combined with chemotherapy or
radiation therapy," Dr. Fan said.
"I want to know why these cells are
so sensitive to C225 so that we can
identify novel molecular targets for
therapeutic interventions.
"To successfully treat cancer,"
he added, "inhibiting growth is not
enough." •
contact Dr.
McConkey at (713) 792-8591, Dr.
Papandreou at (713) 792-2830, or
Dr. Fan at (713) 745-3560.
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Make Cancer Prevention Part
of Your New Year's Resolutions
o od1,,.,e
vy 1999, hello
2000! Like a clean slate, a new year
o.ffers a fresh st
ar t and the chance to make up for some
of the mistakes a
nd excesses of the previous year. With
999 win ding do
wn and a new millennium approaching now zs the Perfect
time to consider some New Year's resolutions
that, can heln reduce
.
.
your chances of developing
r
cancer
and
increase the odds of detectin
g cancer at an early, more treatable stage.

!

Moderate to vigorous exercise just
three or four times a week can help
reduce your cancer risk while making
you look and feel better. Ask your
physician about starting or restarting
a regular exercise program.

___.. ____e-_w_ar'"'e- f�::.::e,�-----a,
Y\.1Y\.! s �"------•

If you haven't had a recent com
plete physical examination, make an
appointment. The American Cancer
Society recommends a cancer-related
checkup every three years for persons
between 20 and 40 years of age and
yearly exams after age 40.
Don't forget to see your dentist
regularly, too. Dentists, as well as
physicians, find oral cancers.

Screening tests for specific can
cers can detect disease early and save
thousands of lives each year. Com' mon tests include mammograms to
check for breast cancer, PSA blood
tests and digital rectal exams for
prostate cancer, and Pap smears for
cervical cancer. Ask your doctor what
tests you should have this year.

Some cancers can be detected by
self-examination. Women should
perform monthly breast self-exams.
Men should do a monthly testicular
self-exam. All adults should check their
skin regularly for signs of skin cancer.
Ask your health professional for
instructions and more information.

About one out of every three
cancer deaths and 85% of lung
cancers are linked to smoking.
Cigarettes, snuff, and chewing
tobacco can also cause cancers of
the bladder, pancreas, mouth, and
throat, as well as other lung diseases,
heart disease, and stroke.
Spouses and children of smokers
are also at increased risk of develop
ing cancer, and young children of
smokers are hospitalized more often
for serious lung problems.
Remember, even if you've smoked
heavily for years, quitting now can
still help reduce your cancer risk.

About 35% of all cancers may
be related to diet. To reduce your
cancer risk, increase your consump
tion of fruits and vegetables (5 to
9 servings a day) and whole-grain
foods (6 to 11 servings daily), and
reduce your intake of meats and
other high-fat foods. A low-fat,
plant-based diet is your best protec
tion against almost all cancers.
Also, watch your alcohol con
sumption. Although moderate alco
hol consumption (a maximum of
two drinks per day) has been shown
to decrease the risk of coronary
heart disease in middle-aged adults,
drinking has been linked to breast,
colon, and liver cancers. Smokers
who drink have a greatly increased
risk of head and neck cancer.

Overexposure to sunlight can cause
skin cancer, the most common-and
most preventable-cancer of all. If
possible, avoid the sun between 11
a.m. and 4 p.m., when the rays are
strongest. If you must be out in the
sun, cover up with clothing and
sunglasses. Use an SPF 15 or higher
sunscreen that protects against both
UV-A and UV-B rays. Teach children to
be sun-wise, too, and always shield
babies from direct sunlight.

It can be hard to make lifestyle
changes and all too easy to put off
taking greater control of our health.
Resolve to prevent cancer today and
take the first step toward enjoying
better health for many years to
come.•

For more information, contact
your physician or contact the
M. D. Anderson Information Line:

(f) (800) 392-1611 within
the United States, or

(f) (713) 792-6161 in Houston

and outside the United States.
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USHERING IN NEW TECHNOLOGIES:

Medical Physidsts Focus on IMRT,
Ultrasound-Guided Brachytherapy
by Dawn Chalaire

T

here is a saying
among those in the
scientific community
that if you want a
simple answer, don't ask a
medical physicist. On the other
hand, if there is a tough prob
lem to solve, you will do well to
have a physicist on your team.

"The one unique thing about
physicists in general is that people
who study physics are taught how
to solve highly technical problems
in innovative and practical ways," said
Kenneth R. Hogstrom, Ph.D., chair
man of the Department of Radiation
Physics, Division of Radiation Oncol
ogy, at The University of Texas M. D.
Anderson Cancer Center. "Physics
teaches you how to reason."
For the most part, modern radia
tion therapy and diagnostic imaging
owe their existence and development
to the thoughts of physicists. Basic
principles underlying the x-ray tube,
computerized tomography, magnetic
resonance imaging, gamma-ray
imaging, and positron emission
tomography were all discovered and
developed into diagnostic medical
devices by physicists and medical
physicists. Similarly, radioactivity,
X rays, the cobalt 60 machine, the
side-coupled electron linear accelera
tor, and heavy-particle accelerators
used in radiation therapy were all
discovered and developed into
therapeutic medical devices by
physicists and medical physicists.
Today, with the advent of faster,
more powerful computers, medical
physicists in radiation oncology are
focusing their minds on more precise
treatment planning and conformal
methods of treatment delivery.

John Antolak, Ph.D., an assistant professor in the
Department of Radiation Physics, calibrates the
positioning of the NOMOS BAT ultrasound probe
to prepare it for use. Ultrasound scans (right) of
the prostate and surrounding organs, using the
NOMOS BAT, are taken before each treatment to
account for any day-to-day changes in position of
the prostate during a course of intensity-modulated
radiation therapy (IMRT).
"In my opinion, the field is
undergoing a significant transition,"
Dr. Hogstrom said. 'We're changing
to conformal therapy-shaping or
conforming the radiation dosage
to the treatment volume that the
radiation oncologist specifies while
delivering a smaller dose to nearby
normal tissues. Advancements in
technology are allowing us to do
this in ways that do not require an
excessive amount of time for treat
ment planning or delivery."
Targeting prostate cancer
with precise treatment delivery
A significant number of recent
advances in radiation oncology at
M. D. Anderson have centered
around treatment of prostate cancer.

According to Dr. Hogstrom, this is
due in part to the large population
of patients with prostate cancer-the
most common cancer among men
and the increasing sophistication of
these patients, who are demanding
more cutting-edge treatments that
have fewer side effects. Among the
arsenal of irradiation tools at M. D.
Anderson designed to combat pros
tate cancer is intensity-modulated
radiation therapy (IMRT), which
uses beams of varying intensity within
a collimated field to deliver a pre
scribed dose to the tumor while
providing maximum sparing to
the adjoining rectum and bladder,
thereby minimizing the side effects
of the treatment.
(Continued on page 6)
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Medical Physicists Usher in New Technologies
( Continued from page

5)

IMRT is typically delivered daily
over a period of about 3 1/ 2 weeks
if used in conjunction with nonintensity modulated conformal
therapy or about 8 to 9 weeks if used
alone. To ensure that the prostate is
targeted accurately each day, variations in its daily position must be
taken into account. The NOMOS
BAT, an ultrasound localization device,
can be used before treatment each
day to determine changes in the
location of the prostate as small as
1 mm from its reference position.
Professor of Radiation Physics
Isaac Rosen, Ph.D., and Assistant
Professor John Antolak, Ph.D., led
the physics effort that resulted in
the clinical implementation of IMRT
using the NOMOS Peacock system.
Presently, medical physicists plan
individual treatments using the
NOMOS Corvus planning system
and then verify the customized beam
delivery for each patient prior to
treatment by measuring dose in
a water-equivalent phantom that
simulates the patient's body. In early
2000, Dr. Hogstrom said, IMRT
using dynamic multileaf collimation
(DMLC) on a Varian linear accelerator will be available. Medical physicists are currently performing dose
measurements and developing
procedures for use of the DMLC.
An alternative to IMRT for
patients with prostate cancer is

ultrasound-guided iodine 125
brachytherapy, in which multiple
radioactive iodine 125 seeds are
implanted into the prostate, using
ultrasound to guide their placement.
For this procedure, the medical
physicist devises a treatment plan
that meets the radiation oncologist's
dose prescription, orders the radioactive seeds, ensures seed integrity and
proper source strength on receipt,
assists the physician in the implant,
calculates the dose distribution, and
ensures the safety of the procedure.
Professor of Radiation Oncology
Alan Pollack, M.D., Ph.D., and
Assistant Professor Lewis Smith, M.D.,
are leading a phase III randomized
study that compares IMRT boost to
iodine 125 implant boost for patients
with intermediate- to high-risk
adenocarcinoma of the prostate.

Calibrating treatment equipment
to ensure accurate dosing
Before advances in technology
can translate into improved patient
outcomes, Dr. Hogstrom said, institutions that offer the procedures must
have two things: strong medical
physics support and physicians who
are experienced in utilizing the
procedures. With new technologies
come more challenges for medical
physicists because new equipment
and techniques introduce a greater
chance for errors. Perhaps the most
important thing that medical physicists do to ensure accuracy is to

John Horton, Ph.D., an
associate professor in the
Department of Radiation
Physics, calibrates iodine
125 seeds before an
ultrasound-guided
brachytherapy prostate
implant. The iodine 125
seeds (above) used for
prostate brachytherapy
implants are 4.5 mm long. '------------'-'=-
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calibrate treatment machines and
verify treatment procedures to make
sure that the proper dose of radiation is delivered to the patient.
''When delivering radiation
treatments, we try to achieve a dose
accuracy of 5%," Dr. Hogstrom said,
"so the machine delivering the dose
should be calibrated to within 2%.
That is the most important thing, to
make sure the machine is delivering
its dose properly."
The medical physicists in the
Radiological Physics Center (RPC) ,
under the direction of William F.
Hanson, Ph.D. , chief of the O utreach
Physics Section, are responsible for
performing quality assurance checks
at the participating institutions and
reviewing the charts of patien ts
entered into National Cancer Institute (NCI) clinical trials of radiation
therapy. Funded by a National
Institutes of Health grant fo r over
30 years, the RPC, which is overseen
by the American Association of
Physicists in Medicine (AAPM) and
whose home base is M. D . Anderson,
monitors about 1,300 institutions,
including M . D. Anderson, in the
United States, Canada, and several
other countries.
"Their job is to make sure that the
dose delivered by Institution A is the
same dose delivered by Institution B
for the NCI-sponsored clinical trials,"
Dr. Hogstrom said.
Ionization chambers, which are
used to calibrate treatment machines,
must also be calibrated regularly.
M. D. Anderson has one of on ly four
AAPM accredited dosimetry calibration laboratories in the United States.
Instruments are sent from all over
the country to be calibrated against
equipment that has, in turn, been
calibrated by the National Institute
of Standards and Technology.
Under the supervision of Associate
Professor of Radiation Physics Marilyn
Stovall, Ph.D. , the Department of
Radiation Physics also offers radiation dosimetry services to institutions
that do not have the facilities to
measure doses for special circumstances. Dosimeters are sent to the
institutions, exposed to radiation,

Answering the Who, What, and How of Medical Physics
What is medical physics?

Medical physics is the application
of concepts and methods of physics
to the diagnosis and treatment of
human disease. Medical physics
essentially began with the discovery of
the X ray and radioactivity by physi
cists Wilhelm Roentgen in 1895 and
Antoine Henri Becquerel in 1896,
followed by Marie and Pierre
Curie's discovery of the radio
active elements of radium and
polonium. Soon after, ionizing
radiation began to be used to
diagnose and treat disease.
Who are medical physicists?

Most medical physicists
have an advanced degree in
medical physics, physics, or a
related field. All have a sound
knowledge of physics and
medical physics and clinical
training in medical physics.
What credentials do medical
physidsts have?

Medical physicists must be certi
fied by a national board, typically the
American Board of Radiology or the
American Board of Medical Physics.
Most medical physicists are certified
in one of three primary disciplines:
1) radiation therapy physics,
2) diagnostic imaging physics, or
3) nuclear medicine physics. Other
specialties include magnetic reso
nance imaging physics, medical
health physics, and hyperthermia
physics.

and mailed back to M. D. Anderson
where the calibration is checked to
ensure that the correct dosage is
being delivered. This service is also
used to check other medical devices
such as blood irradiators.
Meeting the demands
of new technologies

The role of medical physicists
becomes more important as technol
ogy changes. In the early stages of
technological development, equip
ment that must be able to work
together is often made by different

How do medical physicists practice
their profession?

• Medical physicists are responsible
for the safe and optimal utilization
of radiological equipment and
other physical tools used by
physicians to diagnose and treat
human disease. Medical physicists
1) develop specifications for
equipment; 2) perform acceptance
testing to ensure that the equip
ment operates properly; 3)
�����:::::_____
ensure that the installation
site is safe for the patient,
the workers, and the public;
and 4) determine how the
equipment will be used and
commission it.
• Once the equipment is
installed and commissioned,
the medical physicists are
responsible for overseeing
maintenance of the equip
ment and conducting daily,
weekly, monthly, and annual
quality assurance checks.
• Medical physicists develop
class
solutions to treatment
Medical physicist Laura O'Neill, M.S.,
problems
by developing new
(top) verifies beam delivery prior to a
equipment
or new methods of
course of IMRT treatments lTj measuring
using
existing
equipment.
the dose in a treatment delivery verifica
• Medical physicists assist physicians
tion phantom, which is used to simulate
patient anatomy.
in planning specific treatments
or diagnostic tests for individual
The individualized treatment plan (bottom)
patients. As part of that process,
shows the dose distribution achieved using
medical physicists are responsible
IMRT. Note how dosely the prescribed
for daily and weekly checking of
dosage (80 Gy) conforms to the prostate
radiation oncology patients'
volume, which is shown in dark gray.
charts.•

manufacturers and not fully
integrated. Medical physicists are
responsible for, among other things,
configuring the new equipment so
that the different parts are able to
function together. Because the
medical physicists must learn how
to use the new technology first,
it usually falls to them to teach
the radiation therapists, medical
dosimetrists, and radiation oncolo
gists about the benefits and limita
tions of the new technology.
''Within 10 years," Dr. Hogstrom
said, "IMRT will become standard-

ized, but for now, its proper use
requires considerable effort by the
medical physicist. As soon as one
technology becomes standardized,
then there's usually some other new
technology that comes along. For
instance, we are presently studying
the feasibility of offering proton
therapy, which, if implemented,
will be the next major challenge
for our medical physicists." •
contact Dr: Hogstrom
at (713) 792-3216 or Dr: Pollack at
(713) 792-0781.
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Today, at the start of
a new millennium,
we are all reaping
the benefits of
laboratory investigations that began
decades ago in
molecular biology,
biochemistry,
genetics, and
immunology. The
painstaking research of scientists
throughout the world has brought us
much closer to understanding what
causes cancer and to developing more
effective methods for treating this
constellation of diseases.
From personal experience, I can
help illustrate how laboratory research
and medical care are intertwined. In
1983, my colleague Dr. Gordon Sato
and I first demonstrated that blocking
critical growth-promoting signals with
monoclonal antibodies could prevent
cancer cell proliferation. This research
grew out of understanding that small
molecules, called growth factors,
trigger cell growth and division by
binding to specific recep tors on the
cell surface and activating signals
inside the cell.
Our group produced monoclonal
antibodies that could attach tightly to
epidermal growth factor (EGF) receptors
and prevent activation of the growthsignaling pathway necessary for cancer
8 I MD Anderson OncoLog

Senior Vice President
and Chief Academic Officer
Marga ret L. Kripkc, Ph.D.

development. We showed that tr atment
with anti-EGF receptor monoclonal
antibodies could inhibit the growth
of human tumor cell xenografts tran
planted into athymic (nude) mice.
These findings offered a new approach
to cancer therapy and helped pur
intensive research to discover inhibitor
of growth factor receptor .
The receptor blockade cone pt ha
also led to development of th antibod
Herceptin, which can imped proli£ ration of human cancer cell expr in
the HER2 receptor. Clinical trial ha
shown that Herceptin i u eful wh n
given with chemotherapy for advan d
breast cancer.
The anti-EGF receptor monoclonal
antibody, now called C225, ha d monstrated in ongoing clinical trial that
when combined with either radiation
or chemotherapy, it is effective again t
advanced head and neck cancer. Within
a few years, I believe that receptor
blockage therapy will add a new armamen tarium to existing treatments for
many cancers.
Research into the basic mechanism
of cancer and new forms of detection
and treatment are the building blocks
of outstanding patient care. As we mo e
into a new m illennium, we are in the
midst of an explosion- ignited by basic
research- of scientific discoverie that
will light the way to even more clinical
progress in the years ahead.
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